These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24352219)

  • 1. Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis.
    Hoffmann JC; Stabla K; Burchert A; Volkmann T; Bornhäuser M; Thiede C; Neubauer A; Brendel C
    Ann Hematol; 2014 Feb; 93(2):279-85. PubMed ID: 24352219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD34(+) lineage specific donor cell chimerism for the diagnosis and treatment of impending relapse of AML or myelodysplastic syndrome after allo-SCT.
    Rosenow F; Berkemeier A; Krug U; Müller-Tidow C; Gerss J; Silling G; Groth C; Wieacker P; Bogdanova N; Mesters R; Büchner T; Kienast J; Berdel WE; Stelljes M
    Bone Marrow Transplant; 2013 Aug; 48(8):1070-6. PubMed ID: 23376821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.
    Thiede Ch; Lutterbeck K; Oelschlägel U; Kiehl M; Steudel Ch; Platzbecker U; Brendel C; Fauser AA; Neubauer A; Ehninger G; Bornhäuser M
    Ann Hematol; 2002; 81 Suppl 2():S27-8. PubMed ID: 12611065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Das TP; North D; Fleming SA; Tan JLC; Ivey A; Cummings NJ; Spencer A; Patil SS; Widjaja JML; Swain MI; Bourke C; O'Brien ME; Kliman DS; Curtis DJ
    Transplant Cell Ther; 2023 Jul; 29(7):454.e1-454.e8. PubMed ID: 36966870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
    Lange T; Hubmann M; Burkhardt R; Franke GN; Cross M; Scholz M; Leiblein S; Al-Ali HK; Edelmann J; Thiery J; Niederwieser D
    Leukemia; 2011 Mar; 25(3):498-505. PubMed ID: 21135860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monitoring of chimerism in myeloid cells sorting of transplanted patients with acute myeloid leukaemia: a study from Lyon (France)].
    Mollet I; Giannoli C; Rigal D; Michallet M; Dubois V
    Pathol Biol (Paris); 2012 Apr; 60(2):106-11. PubMed ID: 20822866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation.
    Unnikrishnan A; Meacham AM; Goldstein SS; Ta M; Leather HL; Cogle CR; Castillo P; Wingard JR; Norkin M
    Leuk Res; 2018 Nov; 74():110-112. PubMed ID: 30401521
    [No Abstract]   [Full Text] [Related]  

  • 8. Monitoring of hematopoietic chimerism after transplantation for pediatric myelodysplastic syndrome: real-time or conventional short tandem repeat PCR in peripheral blood or bone marrow?
    Willasch AM; Kreyenberg H; Shayegi N; Rettinger E; Meyer V; Zabel M; Lang P; Kremens B; Meisel R; Strahm B; Rossig C; Gruhn B; Klingebiel T; Niemeyer CM; Bader P
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):1918-25. PubMed ID: 25087899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
    Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34
    Indran T; Das T; Muirhead J; O'Brien M; Swain MI; Cirone B; Widjaja J; Patil S; Curtis DJ
    Leuk Res; 2024 Jul; 142():107504. PubMed ID: 38703634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relapse of childhood ALL, AML and MDS after allogeneic stem cell transplantation can be prevented by donor lymphocyte infusion in a critical stage of increasing mixed chimerism].
    Beck JF; Klingebiel T; Kreyenberg H; Schaudt A; Wölle W; Niethammer D; Bader P
    Klin Padiatr; 2002; 214(4):201-5. PubMed ID: 12165902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fast and simple approach for the simultaneous detection of hematopoietic chimerism, NPM1, and FLT3-ITD mutations after allogeneic stem cell transplantation.
    Waterhouse M; Bertz H; Finke J
    Ann Hematol; 2014 Feb; 93(2):293-8. PubMed ID: 23907410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms.
    Jiménez-Velasco A; Barrios M; Román-Gómez J; Navarro G; Buño I; Castillejo JA; Rodríguez AI; García-Gemar G; Torres A; Heiniger AI
    Leukemia; 2005 Mar; 19(3):336-43. PubMed ID: 15674363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripheral blood.
    Fernández-Avilés F; Urbano-Ispizua A; Aymerich M; Colomer D; Rovira M; Martínez C; Nadal E; Talarn C; Carreras E; Montserrat E
    Leukemia; 2003 Mar; 17(3):613-20. PubMed ID: 12646952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.
    Huisman C; de Weger RA; de Vries L; Tilanus MG; Verdonck LF
    Bone Marrow Transplant; 2007 Mar; 39(5):285-91. PubMed ID: 17262061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing the method of chimerism monitoring after allogeneic stem cell transplantation using multiplex polymerase chain reaction amplification of short tandem repeat markers and Amelogenin.
    Sufliarska S; Minarik G; Horakova J; Bodova I; Bojtarova E; Czako B; Mistrik M; Drgona L; Demitrovicova M; Lakota J; Krivosikova M; Kovacs L
    Neoplasma; 2007; 54(5):424-30. PubMed ID: 17688372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia.
    Barrios M; Jiménez-Velasco A; Román-Gómez J; Madrigal ME; Castillejo JA; Torres A; Heiniger A
    Haematologica; 2003 Jul; 88(7):801-10. PubMed ID: 12857560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT.
    Tobiasson M; Olsson R; Hellström-Lindberg E; Mattsson J
    Bone Marrow Transplant; 2011 May; 46(5):719-26. PubMed ID: 20697367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection.
    Dubovsky J; Daxberger H; Fritsch G; Printz D; Peters C; Matthes S; Gadner H; Lion T; Muller-Bérat N
    Leukemia; 1999 Dec; 13(12):2059, 2060-9. PubMed ID: 10602430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High frequency of donor chimerism after allogeneic transplantation of CD34+-selected peripheral blood cells.
    Briones J; Urbano-Ispizua A; Lawler M; Rozman C; Gardiner N; Marín P; Salgado C; Féliz P; McCann S; Montserrat E
    Exp Hematol; 1998 May; 26(5):415-20. PubMed ID: 9590658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.